BR112013001576A2 - composto tetrapirrólico e composição farmacêutica derivado farmacêuticamente aceitável da mesma e respectivos usos e métodos de terapia fotodinâmica e de diagnóstico e tratamento da artrite e de doenças inflamatórias semelhantes. - Google Patents

composto tetrapirrólico e composição farmacêutica derivado farmacêuticamente aceitável da mesma e respectivos usos e métodos de terapia fotodinâmica e de diagnóstico e tratamento da artrite e de doenças inflamatórias semelhantes.

Info

Publication number
BR112013001576A2
BR112013001576A2 BR112013001576A BR112013001576A BR112013001576A2 BR 112013001576 A2 BR112013001576 A2 BR 112013001576A2 BR 112013001576 A BR112013001576 A BR 112013001576A BR 112013001576 A BR112013001576 A BR 112013001576A BR 112013001576 A2 BR112013001576 A2 BR 112013001576A2
Authority
BR
Brazil
Prior art keywords
arthritis
diagnosis
treatment
inflammatory diseases
methods
Prior art date
Application number
BR112013001576A
Other languages
English (en)
Portuguese (pt)
Inventor
Arno Wiehe
Christian B W Stark
Daniel Aicher
Susanna Grafe
Volker Albrecht
Original Assignee
Ceramoptec Gmbh
Ceramoptec Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceramoptec Gmbh, Ceramoptec Ind Inc filed Critical Ceramoptec Gmbh
Publication of BR112013001576A2 publication Critical patent/BR112013001576A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112013001576A 2010-07-22 2011-08-12 composto tetrapirrólico e composição farmacêutica derivado farmacêuticamente aceitável da mesma e respectivos usos e métodos de terapia fotodinâmica e de diagnóstico e tratamento da artrite e de doenças inflamatórias semelhantes. BR112013001576A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36670710P 2010-07-22 2010-07-22
PCT/US2011/047576 WO2012012809A2 (en) 2010-07-22 2011-08-12 APPLICATION OF β-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT

Publications (1)

Publication Number Publication Date
BR112013001576A2 true BR112013001576A2 (pt) 2016-07-19

Family

ID=45497505

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001576A BR112013001576A2 (pt) 2010-07-22 2011-08-12 composto tetrapirrólico e composição farmacêutica derivado farmacêuticamente aceitável da mesma e respectivos usos e métodos de terapia fotodinâmica e de diagnóstico e tratamento da artrite e de doenças inflamatórias semelhantes.

Country Status (8)

Country Link
EP (1) EP2870159B1 (enExample)
JP (1) JP2013532664A (enExample)
CN (1) CN103097390B (enExample)
BR (1) BR112013001576A2 (enExample)
IL (1) IL224381B (enExample)
MX (1) MX353394B (enExample)
PL (1) PL2870159T3 (enExample)
WO (1) WO2012012809A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2616065T3 (pl) * 2010-07-22 2018-05-30 Biolitec Unternehmensbeteiligungs Ii Ag GLIKO-PODSTAWIONE DIHYDROKSYCHLORYNY I ß-FUNKCJONALIZOWANE CHLORYNY DO PRZECIWDROBNOUSTROJOWEJ TERAPII FOTODYNAMICZNEJ
WO2013015774A1 (en) 2011-07-22 2013-01-31 Biolitec Pharma Marketing Ltd Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy
CN103995045A (zh) * 2014-05-29 2014-08-20 武汉矽感科技有限公司 离子迁移谱仪用于检测乐果和马拉硫磷残留的用途及方法
CN107624114B (zh) * 2015-05-07 2021-03-23 卢西蒂恩股份有限公司 甲酰胺卤化的卟啉的低分子量衍生物、即二氢卟酚和菌绿素及其应用
US9722103B2 (en) 2015-06-26 2017-08-01 Sunpower Corporation Thermal compression bonding approaches for foil-based metallization of solar cells
CN104940950B (zh) * 2015-07-09 2017-11-28 武汉大学 一种肿瘤靶向多肽光敏剂键合物
CN111196819B (zh) * 2018-11-16 2023-03-28 中国科学院上海药物研究所 一类d-a-d型苯并吡嗪类化合物及制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648485A (en) * 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
FR2877943B1 (fr) * 2004-11-16 2008-09-05 Univ De Coimbra Nouveaux derives de porphyrine, notamment chlorines et/ou bacteriochlorine, et leurs applications en therapie photodynamique
ES2932287T3 (es) * 2008-09-18 2023-01-17 Biolitec Unternehmensberatungs Ii Ag Método y aplicación novedosos de porfirinas y clorinas meso-sustituidas asimétricamente para TFD
JP6041360B2 (ja) * 2011-07-22 2016-12-07 バイオリテック ウンターネーメンスベタイリグンクス ツヴァイ アクツィエンゲゼルシャフト 抗菌性光線力学療法のための、糖−置換ジヒドロキシ−クロリン及びβ−官能化クロリン

Also Published As

Publication number Publication date
EP2870159A2 (en) 2015-05-13
CN103097390A (zh) 2013-05-08
EP2870159A4 (en) 2015-08-12
MX2013000877A (es) 2013-07-03
PL2870159T3 (pl) 2018-01-31
EP2870159B1 (en) 2017-06-28
IL224381B (en) 2018-03-29
CN103097390B (zh) 2017-03-08
WO2012012809A3 (en) 2012-05-18
MX353394B (es) 2018-01-11
JP2013532664A (ja) 2013-08-19
WO2012012809A2 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
BR112013001576A2 (pt) composto tetrapirrólico e composição farmacêutica derivado farmacêuticamente aceitável da mesma e respectivos usos e métodos de terapia fotodinâmica e de diagnóstico e tratamento da artrite e de doenças inflamatórias semelhantes.
Liu et al. pH-sensitive nano-systems for drug delivery in cancer therapy
BR112012029959A2 (pt) compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo
BR112012013951A2 (pt) formulação farmacêutica de nanopartículas e respectivos métodos de preparação e usos
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
EP2350058A4 (en) NEW METHODS AND USE OF UNSYMMETRIC MESO-SUBSTITUTED PORPHYRINE AND CHLORINE FOR THE PDT
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112012013952A2 (pt) formulação farmacêutica de nanopartículas e respectivos métodos de preparação e usos
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
NZ598137A (en) Oxazine derivatives and their use in the treatment of neurological disorders
EA201200260A1 (ru) Гетероциклические гидразоны и их применение для лечения рака и воспаления
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
AR068816A1 (es) Composiciones de brimonidina mejorada para el tratamiento del eritema
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR112018010879A2 (pt) inibidores da proteína quinase, método de preparação e uso médico dos mesmos
EP4124346A3 (en) Compositions and methods for treating diseases
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
JP2015512386A5 (enExample)
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
Ren et al. Stereocomplex crystallized nanomedical system for enhanced type i pdt and synergistic chemo-phototherapy
MX2009006114A (es) Composiciones que comprenden carisoprodol y metodos de uso de las mismas.
Zhu et al. Recent advances and challenges in metal-based antimicrobial materials: a review of strategies to combat antibiotic resistance

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: CERAMOPTEC GMBH (DE) , CERAMOPTEC INDUSTRIES, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements